NORD Says Orphan Drug Act Is Fine As Is, Wants To Work For Improvements Within System
This article was originally published in The Pink Sheet Daily
The group is afraid asking for wholesale changes to the law would invite too many problems, VP Dorman says at BIO.
You may also be interested in...
If the debate does include a focus on entitlement spending, NORD does not plan on taking sides.
Advocates also are not sure whether to push for a long-term PEPFAR reauthorization; the U.S. expects to release a PEPFAR spending blueprint along with future goals shortly.
FDA appears just as nervous as the National Organization for Rare Disorders about what Congress would do if asked to tweak the Orphan Drug Act.